Top 10 Oncology Capital Raises and Investors in the U.S. – July 16th – August 31st, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PE Growth/Expansion
-
- Resonant Therapeutics, drug discovery platform that helps pharma clients expand their drug discovery pipeline, received development capital from Sweat Equity Partners.
Merger/Acquisition
-
- Aster Insights, health informatics-based tool that accelerates the discovery, development and delivery of personalized medicine for cancer therapies, was acquired by Zephyr AI.
- Capstan Therapeutics, biotechnology platform that expands therapeutic options through targeted in vivo Ribonucleic Acid technologies, was acquired by AbbVie for $2.1 billion.
- Paige, computational pathology module platform for rapid diagnostic stratification and cancer detection, was acquired by Tempus AI for $81.25 million.
Later Stage VC
-
- Angiex, vascular-targeted biotherapeutics for the treatment of solid cancers and other diseases of pathological angiogenesis, raised $10.98 million of venture funding.
- Artax Biopharma, small-molecule drugs that treats autoimmune and inflammatory diseases, raised $11 million of venture funding in the form of convertible debt from Advent Life Sciences, Columbus Venture Partners and other investors.
Early Stage VC
-
- ArteraAI, AI-enabled predictive and prognostic cancer tests that identifies patients who will benefit from therapy intensification, raised venture funding from EnvisionX Capital.
- Corner Therapeutics, biotechnology research services that stimulates exceptional memory T cells for lifelong immunity, raised $58.51 million of Series A venture funding in a deal led by Ziff Capital Partners.
Seed
-
- Inversion Therapeutics, oncology biotech platform that discovers and progresses therapies against previously untapped cancer mechanisms, raised $6.91 million of seed funding in a deal led by Red Tree Venture Capital.
- IsoBio, radiotherapeutic products for cancer treatment, raised $5 million of Seed-1 funding from ASP Isotopes.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
